Pharmala Biotech (MDMA) Q2 2026 earnings summary

Executive summary

• Focused on research, development, and manufacturing of MDXX class molecules, including MDMA, with a growing operational presence in Australia and the U.S.

• Only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials.

• Leadership change announced with the departure of the Chief Commercial Officer by July 2026.

Financial highlights

• Revenues for Q2 2026 were $220,584, up from $145,657 in Q2 2025; six-month revenues reached $487,024, up from $202,954 year-over-year.

• Net loss for Q2 2026 was $337,696, a significant improvement from $810,766 in Q2 2025; six-month net loss was $747,391, down from $1,289,875 year-over-year.

• Customer deposits increased by $310,719 in Q2, with $181,492 recognized as revenue.

• Cash used in operating activities for the six months was $366,396, down from $491,721 in the prior year period.

Outlook and guidance

• Management expects operational know-how and regulatory relationships to drive value as psychedelics move toward commercialization globally.

• Forward-looking statements caution that actual results may differ due to risks and uncertainties.